Schedule 13G ownership disclosure

Keros Therapeutics Inc

Common Stock · CUSIP: 492327101

Event date: 2025-03-31

Filing-level shares
2,566,321
Percent of class
6.32%
  • The Vanguard Group

    Shares: 2,566,321 · Class: 6.32%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000932471-25-000637
Form type
SCHEDULE 13G
Filer
Keros Therapeutics, Inc.
CIK
CIK 1664710
Filed
Apr 30, 2025
Reporting period
Mar 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub